leadf
logo-loader
viewNemaura Medical Inc

Nemaura Medical to Integrate data from third party wearable devices into its proBEAT app

The Loughborough, UK-based med-tech firm plans to launch the proBEAT app in the USA later this year

Nemaura Medical Inc -
Nemaura's tech is aimed at helping people with diabetes and pre-diabetes to better manage, reverse and prevent the disease

Nemaura Medical Inc (NASDAQ:NMRD) revealed it has expanded the scope of its proBEAT monitor, by commissioning the integration of data from other third-party wearable devices into the app.

ProBEAT is a wearable glucose monitor designed to gather big data about the multitude of factors that affect blood glucose levels. The data is then used for predictive algorithms and artificial intelligence-based feedback to go back to wearers (users).

The Loughborough, UK-based med-tech firm plans to launch the proBEAT app in the USA later this year.

READ: Nemaura Medical evaluates new applications for continuous lactate monitoring using its BEAT platform

"The inclusion of data from third-party wearable fitness devices is a significant development and expected to enable the relationship between various activities and factors affecting blood glucose levels to be compared side by side, thus further empowering and educating users of the proBEAT device and app in due course," said Nemaura in a brief statement on Thursday.

Nemaura is advancing micro-systems-based wearable diagnostic devices and is currently commercializing sugarBEAT, which is a non-invasive and flexible continuous glucose monitor (CGM), which may help people with diabetes and pre-diabetes to better manage, reverse and prevent the disease.

ProBEAT comprises a non-invasive glucose monitor and a digital healthcare subscription service and is due to be launched in the US as a general wellness product.

Contact the author at giles@proactiveinvestors.com

Quick facts: Nemaura Medical Inc

Price: 3.75 USD

NASDAQ:NMRD
Market: NASDAQ
Market Cap: $85.85 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Nemaura Medical Inc named herein, including the promotion by the Company of Nemaura Medical Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Full interview: Nemaura Medical reveals details of upcoming European launch...

Nemaura Medical Inc (NASDAQ:NMRD) Vice President of Strategy & Strategic Alliances Dr Fred Schaebsdau tells Proactive the medical technology company is targeting a commercial launch for its flagship SugarBEAT continuous glucose monitor in the UK and in Ireland in January 2020. Dr...

on 10/08/2019

2 min read